Cabinet Office to Organize Society 5.0 Expo to Showcase Japan’s Advanced Technologies and Achievements
14.7.2021 09:00:00 EEST | Business Wire | Press release
The Government of Japan’s Cabinet Office announced that it will organize the Society 5.0 Expo jointly with the Japan Agency for Marine-Earth Science and Technology (JAMSTEC) from 15 July at TOKYO SKYTREE TOWN® in Tokyo, Japan. This is expected to be Japan’s first major expo to focus on Society 5.0. The expo will also be viewable online with multilingual explanations for the global audience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210713006253/en/
[From upper-left] SHINKAI 6500, HAYABUSA2, Wearable Cyborg, Active scope camera for rescue [From lower-left] Ultra-thin and flexible tough polymer, Rescue robot, Small synthetic-aperture radar satellite (SAR), Communication robot, Flying car, Level-3 autonomous vehicle (Photo: Business Wire)
The expo will showcase the Society 5.0 concept proposed by the Japanese government as a highly desirable future society. The concept envisions the creation of a human-centered society in which all industries and other areas of society adopt AI, IoT, robots, big data and other innovative technologies to overcome critical challenges. The Cabinet Office’s 6th Science, Technology and Innovation Basic Plan covering fiscal 2021 to 2025 sets forth the direction of science, technology and innovation policies to secure sustainability, resilience and the well-being of diverse individuals.
The expo will present achievements being realized through national projects focused on increasing innovation in society, including the cross-ministerial strategic innovation promotion program (SIP) and the ImPACT program for stimulating high-risk, high-impact R&D. Japan’s scientific and technological aspirations will be conveyed through numerous displays of advanced technologies.
Specifically, some 50 leading Japanese companies, universities and organizations will exhibit approximately 200 products and research achievements that are expected to contribute not only to Society 5.0 but also the UN’s Sustainable Development Goals. The exhibits will cover fields such as mobility, healthcare and caregiving, manufacturing, agriculture, food, disaster prevention and energy, including:
- Asteroid-explorer Hayabusa2’s returned capsule
- Full-scale model of SHINKAI 6500 submersible piloted to 6,500 meters undersea
- SkyDrive flying car
- Honda Legend Level-3 autonomous vehicle with high-definition 3D mapping
- Model of small synthetic-aperture radar satellite system for on-demand launches and instant observation
- HAL wearable cyborg that transmits brain signals to human muscles for assistance with physical functions
- Disaster-prevention systems for heavy rain and tornado forecasting and ICT-based information sharing
- Smart agriculture technology, such as an automated water supply and drainage system
International viewers will be welcome to enjoy the many exhibits viewable online via mobile devices and PCs, supported with explanations available in a number of languages. The organizers will be pleased to present the virtual exhibition as an opportunity for the global community to learn more about Japan’s forward-looking Society 5.0 concept.
Exhibits will be grouped under the follow themes:
Stage 1 Prologue
The opening theme will present a full-scale model of the SHINKAI 6500 research submersible and a Dagik Earth three-dimensional digital globe, etc. Satellite-based technologies that are being deployed on a practical working basis in various sectors also will be introduced.
Stage 2 Science Frontiers—Space and Ocean
Exhibits of Japan's world-class space-exploration technology will include models of the International Space Station, the "Kibo" Japanese Experiment Module, a full-scale rocket engine, and the Hayabusa2 return capsule.
Exhibits of Japan’s ocean exploration and environmental-simulation technology will include autonomous underwater vehicles for exploring hydrothermal vents and ocean-floor resources and advanced solutions for ocean research.
Stage 3 5.0 Society of the Future
Science and technologies developed through Japan’s SIP and ImPACT programs and how they will help to enhance life in five areas: 1) 100-year lifespans, 2) Mobility and social interaction, 3) Infrastructure for more resilient and safer life, 4) Human- and earth-friendly lifestyles and 5) Advanced manufacturing. Exhibits will include automated solutions such as robots, vehicles and drones, disaster-prevention systems such as AI for infrastructure inspections, robotic industrial borescopes, next-generation energy and resources such as ammonia fuel and ocean-floor minerals, and advanced materials such as synthetic spider silk and strong but flexible ultra-thin polymers.
Stage 4 Trajectory toward Society 5.0
The evolution of human civilization will be presented through videos and other visuals portraying Society 1.0 (hunting & gathering), 2.0 (agriculture), 3.0 (industry) and 4.0 (information) as well as 5.0 (at TOKYO SKYTREE® Tembo Galleria, the closest point to space in Tokyo).
Stage 5 Society 5.0 Theater
Films from the Japan Aerospace Exploration Agency (JAXA) and JAMSTEC will be aired. Also, researchers and experts will give presentations about science, oceans, disaster prevention and ICT for advanced technology and innovation.
Please download official images from here.
Outline of Society 5.0 Expo
|
Organizers |
Cabinet Office and Japan Agency for Marine-Earth Science and Technology (JAMSTEC) |
|
|
Venue |
Exhibition areas within TOKYO SKYTREE TOWN |
|
|
|
- Pavilion at TOKYO SKYTREE TOWN Sky Arena (4F) |
|
|
|
- TOKYO SKYTREE TOWN Solamachi Square (1F) |
|
|
|
- TOKYO SKYTREE Group Floor (1F) |
|
|
|
- TOKYO SKYTREE Tembo Galleria |
|
|
|
- TOKYO SKYTREE TOWN campus of Chiba Institute of Technology |
|
|
|
|
|
|
Dates |
15 July to 5 September 2021 |
|
|
|
- Physical exhibitions by enterprises (15 July to 19 July) |
|
|
|
- Physical exhibitions by other organizations (15 July to 28 July) |
|
|
|
- Sub-exhibition by posters and videos (15 July to 5 September) |
|
|
|
- Virtual exhibition (17 July to 5 September) with multi-language explanations
|
|
|
Admission |
Free (Admission to sub-exhibition by ticket, sold at TOKYO SKYTREE Tembo Galleria) |
|
|
Exhibitors and partners |
Please refer to the list on the official website |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713006253/en/
Contact information
Society 5.0 media inquiries
Weber Shandwick
Mayuko Harada (+81-90-9006-4968)
Rina Uesugi (+81-90-2280-0041)
E-mail: society5.0expo@webershandwick.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom